"","submission_name","submission_date","template_name","tissue_type","response_component_original","response_behavior_type","response_behavior","comparison","subgroup","time_point","time_point_units","baseline_time_event","target_pathogen","vaccine_year","exposure_material_id","additional_exposure_material","cohort","adjuvant","route","publication_reference_id","publication_year","publication_date","signature_source","signature_source_url","comments","is_model","publication_reference_url","age_group","age_min","age_max","age_units","curator_comments","response_component","response_comp_orig_cnt","response_comp_cnt","subm_obs_id","uniq_obs_id","row_key","signature_file","signature_file_complete"
"subject","","","","cell_subset","","","","","","","","","pathogen","","vaccine","","","","","","","","","","","","","","","","","","","","","","","","",""
"evidence","","","","","label","label","label","label","label","label","label","label","","label","","label","label","label","label","label","label","label","label","label","label","label","url","label","label","label","label","label","","label","label","label","label","label","file","file"
"role","","","","tissue","observed","background","measured","background","background","observed","observed","background","pathogen","background","vaccine","background","observed","background","background","background","background","background","background","background","background","background","reference","observed","observed","observed","observed","observed","","observed","observed","background","background","background","observed","observed"
"mime_type","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"numeric_units","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"display_text","","","","tissue type","response component (original gene symbol)","response behavior type","response behavior","comparison","subgroup","time point","time point units","baseline time","target pathogen","vaccine year (influenza only)","exposure material (VO)","exposure material - additional","cohort","adjuvant","route","publication reference (PMID)","publication year","publication date","signature source figure, table or text section ","signature source url","comments and additional details","gene signature is a model","Sobolev et al. (2016) Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. PMID: <a href = 'https://www.ncbi.nlm.nih.gov/pubmed/?term=26726811' target='_blank'>26726811</a>","age group","age min.","age max.","age units","will not appear in Dashboard","","response component (original) count","response component count","ID of observation within its own submission","Uniq ID of observation within its submission type","row key","response component (genes) file"," response components including non-HGNC genes"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","VMO1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","VMO1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","CD19","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","CD19","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","FCRL1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","FCRL1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","BANK1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","BANK1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","FCRLA","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","FCRLA","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","P2RX5","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","P2RX5","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","FCRL2","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","FCRL2","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","CD79B","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","CD79B","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","MS4A1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","MS4A1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","NIBAN3","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","NIBAN3","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","PCDH9","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","PCDH9","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","RUBCNL","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","RUBCNL","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","CD22","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","CD22","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","EBF1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","EBF1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","CD72","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","CD72","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","FCER2","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","FCER2","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","CNR2","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","CNR2","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","TSPAN13","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","TSPAN13","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","PAWR","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","PAWR","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","LARGE1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","LARGE1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
"","hipc_gene_26726811_6","2016.02","hipc_gene_26726811_6","peripheral blood mononuclear cell","SETBP1","gene expression","up-regulated","high vs low responders","medium-high adverse events score","1","Day","time of vaccination (first dose)","influenza A virus (A/California/7/2009(H1N1))","pan","VO_0000410","","adults (18-64)","","","26726811","2016","","Fig 6a, Suppl Fig 8a","<a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/' target='_blank'>figure/F6</a>; <a href = 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf' target='_blank'>supplement-1.pdf</a>","Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","N","https://www.ncbi.nlm.nih.gov/pubmed/26726811","adults, seniors","18","64","years","","SETBP1","21","21","6","57","26726811_6_57","hipc_gene_sig_26726811_6.txt","hipc_gene_sig_complete_26726811_6.txt"
